Open-label Extension (OLE) Study to Assess Safety and Efficacy of Evolocumab

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A MULTICENTER, OPEN-LABEL EXTENSION (OLE) STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF EVOLOCUMAB

Intervention/treatment:
AMG 145 (EVOLOCUMAB) / LIPITOR
Medical condition:
HYPERCHOLESTEROLEMIA
Protocol code:
20140128
Control number:
177553
Status:
Closed
Approved:
September 26, 2014
Date Completed:
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT02304484
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years to 99 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Study Director
Organization
Amgen Inc.
Phone:
866-572-6436
Sponsor
AMGEN CANADA INC

Locations

Alberta

Research Site
Calgary, Alberta, T2N 4Z6

British Columbia

Research Site
Victoria, British Columbia, V8R 4R2

Manitoba

Research Site
Winnipeg, Manitoba, R2H 2A6

Newfoundland and Labrador

Research Site
St. John's, Newfoundland and Labrador, A1B 3V6

Nova Scotia

Research Site
Halifax, Nova Scotia, B3H 3A7

Ontario

Research Site
London, Ontario, N6A 5A5
Research Site
Toronto, Ontario, M5B 1W8
Research Site
Toronto, Ontario, M5G 2C4

Quebec

Research Site
Laval, Quebec, H7M 3L9
Research Site
Montreal, Quebec, H1T 2M4
Research Site
Québec, Quebec, G1V 4G5

Results

See the results from the trial NCT02304484. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?